Bbibp corv

Venous blood was collected in dry tubes and centrifuged at 900g for 10 minutes. Serum supernatants were stored at -20°C. Serum samples were collected from COVID-19 patients at various time points after symptom onset, including 2–5 days (D00), 9–12 days (D07), 17–20 days (D15), 32–37 days (D30), 62–67 days (D60), 92–98 days (D90), 182–188 days (D180), and 363–367 days (D360). Participants were separated into two groups: one group consisted of infected and unvaccinated patients over a 12-month period, while the other group consisted of patients who had been vaccinated with ChAdOx1 nCoV-19 (AstraZeneca) before infection. Patients who received mRNA or vector vaccines (Pfizer, AstraZeneca, Johnson) during follow-up were excluded from the anti-RBD IgG antibody analysis, and patients who received BBIBP-CorV (Sinopharm) were excluded from all analyses. Furthermore, throughout the study, some patients were excluded for other reasons, such as relocation from the city, hospitalization and unavailability due to work. Samples from patients reinfected with SARS-CoV-2 between study visits were not included.

Eight-week-old female BALB/c or C57BL/6 mice were obtained from IIB-UNSAM animal facility. For immunogenicity studies, animals were intramuscularly (i.m) inoculated at day 0 and 14 with (i) Gamma RBD (10 µg) + Alum (100 µg), (ii) Ancestral RBD (10 µg) + Alum (100 µg) or (iii) placebo (Alum alone). In other experiments, BALB/c mice were vaccinated with: (i) Gamma RBD (10 µg) + Alum (100 µg) or (ii) placebo. A group containing ancestral spike 2 P (5 µg, BPS Biosciences) and Alum (100 µg) was used as control in some experiments. Blood samples were collected weekly to measure total and neutralizing antibody titers and at day 42 post prime immunization animals were sacrificed and spleens harvested.
In booster experiments, eight-week-old female BALB/c mice were i.m inoculated on days 0 and 21 with (i) Gamma RBD (10 µg/dose) + Alum (100 µg/dose, n = 5 mice), (ii) Comirnaty (1 µg/dose) (Pfizer-BioNTech, n = 10 mice), (iii) BBIBP-CorV (1.3 U/dose containing 45 µg of Alum) (Sinopharm, n = 10 mice), (iv) and ChAdOx1 nCoV-19 (3 × 10⁹ particles/dose) (Oxford-AstraZeneca, n = 10 mice). At day 99, 5 animals per group were boosted with the Gamma RBD (10 µg) + Alum (100 µg) while the other 5 animals received the homologous vaccine. Blood samples were collected weekly to measure total and neutralizing antibody titers.

An online survey was designed to detect the postvaccine side effects. Healthy subjects who received two doses of BBIBP-CorV (Sinopharm), ChAdOx1 (AstraZeneca), or BNT162 (Pfizer BioNTech) vaccines participated in the study. A total of 168 participants participated in the study. The sample size was determined according to the previous report [14 (link)].
From the total participants, 78 participants recalled and agreed to undergo IgG anti-spike-protein antibodies tests after three days and three weeks after the first dose of vaccination with the BBIBP-CorV or ChAdOx1 vaccines, and three weeks after the second dose of vaccination with the BBIBP-CorV or ChAdOx1 vaccines.

The study was conducted in two parts. First, an online survey using the WeChat Questionnaire Star software were conducted. 424 healthy adults aged 18-70 years and healthy teenagers aged 12-18 years completed the survey. Second, we recruited 60 volunteers for the trial. They received three doses of the BBIBP-CorV (Sinopharm) or CoronaVac (Sinovac Biotech) COVID-19 inactivated vaccine. The boosting effect of the three vaccine doses was evaluated for safety, reactogenicity, and immunogenicity at 7, 14, 21, 28, and 56 days after vaccination. The study was conducted accordance with the guidelines of the Declaration of Helsinki and was approved by the Institutional Review Board of the Ethics Committee of Jinan Central Hospital (Ethical code No. D202111Ab). All participants provided written informed consents. Questionnaire and informed consent forms are available upon request.

Prior approval had been granted by institutional review boards (IRBs) under the Agency for Science Technology and Research (A*STAR) to Singapore Immunology Network for the conduct of this study. Healthy donors who were above the age of 21 and due for their COVID-19 vaccine booster were recruited under a Singapore Immunology Network study entitled, “Study of B cell immune responses to SARS-CoV2 vaccine”. These donors either received the mRNA (BNT162b2, Pfizer-BioNTech/COMIRNATY or mRNA-1273, Moderna) or an inactivated virus (CoronaVac, Sinovac or BBIBP-CorV, Sinopharm) vaccine as their third dose booster. These individuals were not infected with SARS-CoV2 before or during the study. Peripheral blood was collected before the booster dose and on day 28 (±5) after the booster. A total of 66 subjects were recruited for this study, 29 males and 37 females. Written informed consent was obtained from all donors in accordance with the Declaration of Helsinki for Human Research.